Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Virology Retrieve available abstracts of 112 articles: HTML format

Single Articles

September 2023
1. BRIGGS K, Sweeney R, Blehert DS, Spackman E, et al
   SARS-CoV-2 utilization of ACE2 from different bat species allows for virus entry and replication in vitro.
   Virology. 2023;586:122-129.
   PubMed     Abstract available
   
   
   
2. RAMIREZ KA, Mond J, Papenburg J, Boivin G, et al
   In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.
   Virology. 2023;586:115-121.
   PubMed     Abstract available
   
   
   
3. XIAO Y, Wang L, Fang SS, Luo F, et al
   Direct blue 53, a biological dye, inhibits SARS-CoV-2 infection by blocking ACE2 and spike interaction in vitro and in vivo.
   Virology. 2023;586:105-114.
   PubMed     Abstract available
   
   
   August 2023
4. TEWARI DN, Biswas A, Chakrabarti AK, Dutta S, et al
   AMFR promotes innate immunity activation and proteasomal degradation of HMGCR in response to influenza virus infection in A549 cells.
   Virology. 2023;587:109875.
   PubMed     Abstract available
   
   
   
5. UPRETY T, Sreenivasan CC, Thomas M, Hause B, et al
   Prevalence and characterization of seven-segmented influenza viruses in bovine respiratory disease complex.
   Virology. 2023;587:109859.
   PubMed     Abstract available
   
   
   
6. YOUK S, Torchetti MK, Lantz K, Lenoch JB, et al
   H5N1 highly pathogenic avian influenza clade 2.3.4.4b in wild and domestic birds: Introductions into the United States and reassortments, December 2021-April 2022.
   Virology. 2023;587:109860.
   PubMed     Abstract available
   
   
   July 2023
7. ZHOU H, Liu J, Li L, Sun J, et al
   Circulation of influenza C virus of C/Sao Paulo/378/82 lineage among pediatric acute respiratory cases, Shandong, China.
   Virology. 2023;587:109855.
   PubMed     Abstract available
   
   
   June 2023
8. TANG L, Liu X, Wang C, Shu C, et al
   USP18 promotes innate immune responses and apoptosis in influenza A virus-infected A549 cells via cGAS-STING pathway.
   Virology. 2023;585:240-247.
   PubMed     Abstract available
   
   
   
9. YILMAZ B, Cakmak Genc G, Karakas Celik S, Piskin N, et al
   The 3'UTR region of the DNA repair gene PARP-1 May increase the severity of COVID-19 by altering the binding of antiviral miRNAs.
   Virology. 2023;583:29-35.
   PubMed     Abstract available
   
   
   
10. POTTAGE T, Onianwa O, Atkinson B, Spencer A, et al
    Stability of SARS-CoV-2 variants of concern (Delta and Omicron) on surfaces at room temperature.
    Virology. 2023;583:27-28.
    PubMed     Abstract available
    
    
    
11. PFANZAGL B
    The ICAM-1 ligand HRV-A89 is internalized independently of clathrin-mediated endocytosis and its capsid reaches late endosomes.
    Virology. 2023;583:45-51.
    PubMed     Abstract available
    
    
    May 2023
12. CHENCHULA S, Amerneni KC, Ghanta MK, Padmavathi R, et al
    Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review.
    Virology. 2023;584:38-43.
    PubMed     Abstract available
    
    
    
13. SUN X, Belser JA, Kieran TJ, Brock N, et al
    Enhanced fitness of SARS-CoV-2 B.1.617.2 Delta variant in ferrets.
    Virology. 2023;582:57-61.
    PubMed     Abstract available
    
    
    
14. MAYER AM, Grohs Ferrareze PA, de Oliveira LFV, Gregianini TS, et al
    Genomic characterization and molecular evolution of SARS-CoV-2 in Rio Grande do Sul State, Brazil.
    Virology. 2023;582:1-11.
    PubMed     Abstract available
    
    
    April 2023
15. BOSCO-LAUTH A, Rodriguez A, Maison RM, Porter SM, et al
    H7N9 influenza A virus transmission in a multispecies barnyard model.
    Virology. 2023;582:100-105.
    PubMed     Abstract available
    
    
    
16. KANDWAL S, Fayne D
    Genetic conservation across SARS-CoV-2 non-structural proteins - Insights into possible targets for treatment of future viral outbreaks.
    Virology. 2023;581:97-115.
    PubMed     Abstract available
    
    
    March 2023
17. HUONG TN, Ravi Iyer L, Lui J, Wang Y, et al
    The respiratory syncytial virus SH protein is incorporated into infectious virus particles that form on virus-infected cells.
    Virology. 2023;580:28-40.
    PubMed     Abstract available
    
    
    December 2022
18. VILLA R, Renzi S, Dotti S, Lucchini F, et al
    siRNAs pools generated in Escherichia coli exhibit strong RNA-interference activity against influenza virus genomic sequences.
    Virology. 2022;579:38-45.
    PubMed     Abstract available
    
    
    
19. TARE DS, Pawar SD, Keng SS, Kode SS, et al
    The evolution, characterization and phylogeography of avian influenza H9N2 viruses from India.
    Virology. 2022;579:9-28.
    PubMed     Abstract available
    
    
    
20. DEHGANI-MOBARAKI P, Wang C, Floridi A, Floridi E, et al
    Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model
    Virology. 2022;578:111-116.
    PubMed     Abstract available
    
    
    November 2022
21. HIONO T, Kobayashi D, Kobayashi A, Suzuki T, et al
    Virological, pathological, and glycovirological investigations of an Ezo red fox and a tanuki naturally infected with H5N1 high pathogenicity avian influenza viruses in Hokkaido, Japan.
    Virology. 2022;578:35-44.
    PubMed     Abstract available
    
    
    
22. FIGUEIREDO-NUNES I, Trigueiro-Louro J, Rebelo-de-Andrade H
    Exploring new antiviral targets for influenza and COVID-19: Mapping promising hot spots in viral RNA polymerases.
    Virology. 2022;578:45-60.
    PubMed     Abstract available
    
    
    
23. SANTOS LA, Almeida F, Giria M, Trigueiro-Louro J, et al
    Adaptive evolution of PB1 from influenza A(H1N1)pdm09 virus towards an enhanced fitness.
    Virology. 2022;578:1-6.
    PubMed     Abstract available
    
    
    October 2022
24. LIANG Y, Hjulsager CK, Seekings AH, Warren CJ, et al
    Pathogenesis and infection dynamics of high pathogenicity avian influenza virus (HPAIV) H5N6 (clade 2.3.4.4b) in pheasants and onward transmission to chickens.
    Virology. 2022;577:138-148.
    PubMed     Abstract available
    
    
    
25. TANIKAWA T, Fujii K, Sugie Y, Tsunekuni R, et al
    Ubiquitin-specific protease 18 in mallard (Anas platyrhynchos) interferes with type I interferon-mediated inhibition of high pathogenicity avian influenza virus replication.
    Virology. 2022;577:32-42.
    PubMed     Abstract available
    
    
    
26. BRAKEL KA, Ma Y, Binjawadagi R, Harder O, et al
    Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model.
    Virology. 2022;575:101-110.
    PubMed     Abstract available
    
    
    
27. AMIDEI A, Dobrovolny HM
    Estimation of virus-mediated cell fusion rate of SARS-CoV-2.
    Virology. 2022;575:91-100.
    PubMed     Abstract available
    
    
    
28. MONTEIRO A, Chang AJ, Welliver RR, Baron S, et al
    Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease.
    Virology. 2022;575:83-90.
    PubMed     Abstract available
    
    
    
29. POPOVIC M
    Strain wars 4 - Darwinian evolution through Gibbs' glasses: Gibbs energies of binding and growth explain evolution of SARS-CoV-2 from Hu-1 to BA.2.
    Virology. 2022;575:36-42.
    PubMed     Abstract available
    
    
    September 2022
30. TANG CY, Boftsi M, Staudt L, McElroy JA, et al
    SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021-2022 influenza season.
    Virology. 2022;576:105-110.
    PubMed     Abstract available
    
    
    
31. WANG R, Huang X, Cao T, Sun C, et al
    Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants.
    Virology. 2022;576:61-68.
    PubMed     Abstract available
    
    
    
32. YAN H, Liu Z, Yan G, Liu X, et al
    A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors.
    Virology. 2022;574:18-24.
    PubMed     Abstract available
    
    
    August 2022
33. ABDELKADER A, Elzemrany AA, El-Nadi M, Elsabbagh SA, et al
    In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
    Virology. 2022;573:96-110.
    PubMed     Abstract available
    
    
    
34. AL-ZYOUD W, Haddad H
    Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion.
    Virology. 2022;573:84-95.
    PubMed     Abstract available
    
    
    July 2022
35. WANG T, Wei F, Jiang Z, Song J, et al
    Influenza virus NS1 interacts with 14-3-3epsilon to antagonize the production of RIG-I-mediated type I interferons.
    Virology. 2022;574:47-56.
    PubMed     Abstract available
    
    
    
36. HAN M, Gao S, Hu W, Zhou Q, et al
    Inhibitory effects of cedar pine needle extract on H9N2 avian influenza virus in vitro and in vivo.
    Virology. 2022;574:25-36.
    PubMed     Abstract available
    
    
    
37. GE Y, Liu K, Chi Y, Zhu X, et al
    Exosomal microRNA expression profiles derived from A549 human lung cells in response to influenza A/H1N1pdm09 infection.
    Virology. 2022;574:9-17.
    PubMed     Abstract available
    
    
    
38. OH J, Subbiah J, Kim KH, Park BR, et al
    Impact of hemagglutination activity and M2e immunity on conferring protection against influenza viruses.
    Virology. 2022;574:37-46.
    PubMed     Abstract available
    
    
    
39. KUMAR P, Mathayan M, Smieszek SP, Przychodzen BP, et al
    Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
    Virology. 2022;572:64-71.
    PubMed     Abstract available
    
    
    
40. PONDE RAA
    Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.
    Virology. 2022;572:44-54.
    PubMed     Abstract available
    
    
    June 2022
41. GUAN M, Jacobson O, Sarafianos G, Baroch J, et al
    Exposure of white-tailed deer in North America to influenza D virus.
    Virology. 2022;573:111-117.
    PubMed     Abstract available
    
    
    
42. LIM H, Kim SE, Lee YH, Hwang YH, et al
    Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
    Virology. 2022;573:118-123.
    PubMed     Abstract available
    
    
    
43. ZHU Y, Scholle F, Kisthardt SC, Xie DY, et al
    Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E.
    Virology. 2022;571:21-33.
    PubMed     Abstract available
    
    
    May 2022
44. KHAN K, Khan SA, Jalal K, Ul-Haq Z, et al
    Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.
    Virology. 2022;572:28-43.
    PubMed     Abstract available
    
    
    
45. ZMASEK CM, Lefkowitz EJ, Niewiadomska A, Scheuermann RH, et al
    Genomic evolution of the Coronaviridae family.
    Virology. 2022;570:123-133.
    PubMed     Abstract available
    
    
    
46. POPOVIC M
    Strain wars 2: Binding constants, enthalpies, entropies, Gibbs energies and rates of binding of SARS-CoV-2 variants.
    Virology. 2022;570:35-44.
    PubMed     Abstract available
    
    
    
47. EL-ASHREY MK, Bakr RO, Fayed MAA, Refaey RH, et al
    Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease.
    Virology. 2022;570:18-28.
    PubMed     Abstract available
    
    
    April 2022
48. PUCHINGER K, Castelletti N, Rubio-Acero R, Geldmacher C, et al
    The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 cases.
    Virology. 2022;569:37-43.
    PubMed     Abstract available
    
    
    
49. MI T, Wang T, Xu H, Sun P, et al
    Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.
    Virology. 2022;569:56-63.
    PubMed     Abstract available
    
    
    
50. SARKAR L, Oko L, Gupta S, Bubak AN, et al
    Azadirachta indica A. Juss bark extract and its Nimbin isomers restrict beta-coronaviral infection and replication.
    Virology. 2022;569:13-28.
    PubMed     Abstract available
    
    
    
51. KAPCZYNSKI DR, Sweeney R, Spackman E, Pantin-Jackwood M, et al
    Development of an in vitro model for animal species susceptibility to SARS-CoV-2 replication based on expression of ACE2 and TMPRSS2 in avian cells.
    Virology. 2022;569:1-12.
    PubMed     Abstract available
    
    
    March 2022
52. MOGRO EG, Bottero D, Lozano MJ
    Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic.
    Virology. 2022;568:56-71.
    PubMed     Abstract available
    
    
    
53. XU H, Akinyemi IA, Chitre SA, Loeb JC, et al
    SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway.
    Virology. 2022;568:13-22.
    PubMed     Abstract available
    
    
    February 2022
54. CHEN X, Sun HY, Lee CY, Rostad CA, et al
    Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.
    Virology. 2022;569:44-55.
    PubMed     Abstract available
    
    
    January 2022
55. CHEN Z, Zeng Y, Wei Y, Wang Q, et al
    Influenza D virus Matrix protein 1 restricts the type I interferon response by degrading TRAF6.
    Virology. 2022;568:1-11.
    PubMed     Abstract available
    
    
    
56. AFRIN SZ, Islam MT, Paul SK, Kobayashi N, et al
    Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021.
    Virology. 2022;565:29-37.
    PubMed     Abstract available
    
    
    
57. SODERLUND-VENERMO M, Varma A, Guo D, Gladue DP, et al
    World Society for Virology first international conference: Tackling global virus epidemics.
    Virology. 2022;566:114-121.
    PubMed     Abstract available
    
    
    
58. NADERI N, Rahimzadeh M
    Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
    Virology. 2022;566:106-113.
    PubMed     Abstract available
    
    
    
59. RAYMONDA MH, Ciesla JH, Monaghan M, Leach J, et al
    Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
    Virology. 2022;566:60-68.
    PubMed     Abstract available
    
    
    
60. KUMAR P, Bhardwaj T, Garg N, Giri R, et al
    Microsecond simulations and CD spectroscopy reveals the intrinsically disordered nature of SARS-CoV-2 spike-C-terminal cytoplasmic tail (residues 1242-1273) in isolation.
    Virology. 2022;566:42-55.
    PubMed     Abstract available
    
    
    December 2021
61. PARK BR, Subbiah J, Kim KH, Kwon YM, et al
    Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
    Virology. 2021;566:143-152.
    PubMed     Abstract available
    
    
    
62. HEINIMAKI S, Lampinen V, Tamminen K, Hankaniemi MM, et al
    Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
    Virology. 2021;566:89-97.
    PubMed     Abstract available
    
    
    
63. HU Z, Chen JP, Xu JC, Chen ZY, et al
    A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.
    Virology. 2021;566:56-59.
    PubMed     Abstract available
    
    
    November 2021
64. TRIGUEIRO-LOURO J, Santos LA, Almeida F, Correia V, et al
    NS1 protein as a novel anti-influenza target: Map-and-mutate antiviral rationale reveals new putative druggable hot spots with an important role on viral replication.
    Virology. 2021;565:106-116.
    PubMed     Abstract available
    
    
    
65. GONG SY, Chatterjee D, Richard J, Prevost J, et al
    Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.
    Virology. 2021;563:134-145.
    PubMed     Abstract available
    
    
    
66. RAI P, Chuong C, LeRoith T, Smyth JW, et al
    Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis.
    Virology. 2021;563:98-106.
    PubMed     Abstract available
    
    
    
67. ABDELHAFIZ AS, Fouad MA, Sayed-Ahmed MM, Kamel MM, et al
    Upregulation of FOXP3 is associated with severity of hypoxia and poor outcomes in COVID-19 patients.
    Virology. 2021;563:74-81.
    PubMed     Abstract available
    
    
    
68. HARDER OE, Martinez M, Niewiesk S
    Nonsteroidal anti-inflammatory drugs restore immune function to respiratory syncytial virus in geriatric cotton rats (Sigmodon hispidus).
    Virology. 2021;563:28-37.
    PubMed     Abstract available
    
    
    October 2021
69. AHMED SM, Nasr MA, Elshenawy SE, Hussein AE, et al
    BCG vaccination and the risk of COVID 19: A possible correlation.
    Virology. 2021;565:73-81.
    PubMed     Abstract available
    
    
    
70. ZHANG G, Ng F, Chen M
    Short-hairpin RNAs delivered by recombinant adeno-associated virus inhibited the replication of influenza A viruses in vitro.
    Virology. 2021;564:46-52.
    PubMed     Abstract available
    
    
    
71. BYRD-LEOTIS L, Lasanajak Y, Bowen T, Baker K, et al
    SARS-CoV-2 and other coronaviruses bind to phosphorylated glycans from the human lung.
    Virology. 2021;562:142-148.
    PubMed     Abstract available
    
    
    
72. TAGHIZADEH P, Salehi S, Heshmati A, Houshmand SM, et al
    Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains.
    Virology. 2021;562:63-73.
    PubMed     Abstract available
    
    
    
73. DEUTSCHMANN-OLEK KM, Yue WW, Bezerra GA, Skern T, et al
    Defining substrate selection by rhinoviral 2A proteinase through its crystal structure with the inhibitor zVAM.fmk.
    Virology. 2021;562:128-141.
    PubMed     Abstract available
    
    
    September 2021
74. WELCH M, Park J, Harmon K, Zhang J, et al
    Pathogenesis of a novel porcine parainfluenza virus type 1 isolate in conventional and colostrum deprived/caesarean derived pigs.
    Virology. 2021;563:88-97.
    PubMed     Abstract available
    
    
    
75. VERMA J, Subbarao N
    Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability.
    Virology. 2021;561:107-116.
    PubMed     Abstract available
    
    
    
76. PLAAS M, Seppa K, Gaur N, Kasenomm P, et al
    Age- and airway disease related gene expression patterns of key SARS-CoV-2 entry factors in human nasal epithelia.
    Virology. 2021;561:65-68.
    PubMed     Abstract available
    
    
    August 2021
77. MENNE Z, Pliasas VC, Compans RW, Glover S, et al
    Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.
    Virology. 2021;562:197-208.
    PubMed     Abstract available
    
    
    
78. NAEMI FMA, Al-Adwani S, Al-Khatabi H, Al-Nazawi A, et al
    Frequency of HLA alleles among COVID-19 infected patients: Preliminary data from Saudi Arabia.
    Virology. 2021;560:1-7.
    PubMed     Abstract available
    
    
    July 2021
79. CHEN X, Rostad CA, Anderson LJ, Sun HY, et al
    The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
    Virology. 2021;559:1-9.
    PubMed     Abstract available
    
    
    June 2021
80. ICHIMIYA T, Okamatsu M, Kinoshita T, Kobayashi D, et al
    Sulfated glycans containing NeuAcalpha2-3Gal facilitate the propagation of human H1N1 influenza A viruses in eggs.
    Virology. 2021;562:29-39.
    PubMed     Abstract available
    
    
    
81. UEDA H, Yamakawa N, Takeuchi K
    Amino- and carboxyl-terminal ends of the bovine parainfluenza virus type 3 matrix protein are important for virion and virus-like particle release.
    Virology. 2021;561:17-27.
    PubMed     Abstract available
    
    
    
82. SUN H, Liu J, Xiao Y, Duan Y, et al
    Pathogenicity of novel reassortant Eurasian avian-like H1N1 influenza virus in pigs.
    Virology. 2021;561:28-35.
    PubMed     Abstract available
    
    
    
83. TERRY JS, Anderson LB, Scherman MS, McAlister CE, et al
    Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
    Virology. 2021;558:28-37.
    PubMed     Abstract available
    
    
    
84. NAYAK K, Gottimukkala K, Kumar S, Reddy ES, et al
    Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.
    Virology. 2021;558:13-21.
    PubMed     Abstract available
    
    
    May 2021
85. CASE JB, Winkler ES, Errico JM, Diamond MS, et al
    On the road to ending the COVID-19 pandemic: Are we there yet?
    Virology. 2021;557:70-85.
    PubMed     Abstract available
    
    
    
86. DJUKIC T, Mladenovic M, Stanic-Vucinic D, Radosavljevic J, et al
    Expression, purification and immunological characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2.
    Virology. 2021;557:15-22.
    PubMed     Abstract available
    
    
    April 2021
87. UPRETY T, Sreenivasan CC, Bhattarai S, Wang D, et al
    Isolation and development of bovine primary respiratory cells as model to study influenza D virus infection.
    Virology. 2021;559:89-99.
    PubMed     Abstract available
    
    
    
88. WATERS K, Wan HJ, Han L, Xue J, et al
    Variations outside the conserved motifs of PB1 catalytic active site may affect replication efficiency of the RNP complex of influenza A virus.
    Virology. 2021;559:145-155.
    PubMed     Abstract available
    
    
    
89. NOLAN KE, Baer LA, Karekar P, Nelson AM, et al
    Metabolic shifts modulate lung injury caused by infection with H1N1 influenza A virus.
    Virology. 2021;559:111-119.
    PubMed     Abstract available
    
    
    
90. STAUFT CB, Lien CZ, Selvaraj P, Liu S, et al
    The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.
    Virology. 2021;556:96-100.
    PubMed     Abstract available
    
    
    
91. DETSIKA MG, Ampelakiotou K, Grigoriou E, Psarra K, et al
    A novel ratio of CD8(+):B-cells as a prognostic marker of coronavirus disease 2019 patient progression and outcome.
    Virology. 2021;556:79-86.
    PubMed     Abstract available
    
    
    
92. ZHIRNOV OP, Chlanda P
    The cleavage of spike protein capital EN, Cyrilliccapital A, Cyrillic0-->capital EN, Cyrilliccapital A, Cyrillic1/HA2 by trypsin permits activation of the M2 channel without its proteolytic cleavage in the influenza A virus.
    Virology. 2021;559:86-88.
    PubMed     Abstract available
    
    
    March 2021
93. SEEKINGS AH, Warren CJ, Thomas SS, Mahmood S, et al
    Highly pathogenic avian influenza virus H5N6 (clade 2.3.4.4b) has a preferable host tropism for waterfowl reflected in its inefficient transmission to terrestrial poultry.
    Virology. 2021;559:74-85.
    PubMed     Abstract available
    
    
    
94. WOLF JJ, Xia C, Studstill CJ, Ngo H, et al
    Influenza A virus NS1 induces degradation of sphingosine 1-phosphate lyase to obstruct the host innate immune response.
    Virology. 2021;558:67-75.
    PubMed     Abstract available
    
    
    
95. XIE L, Yi K, Li Y
    SARS_CoV2 RBD gene transcription cannot be driven by CMV promoter.
    Virology. 2021;558:22-27.
    PubMed     Abstract available
    
    
    
96. LU KT, Yamamoto T, McDonald D, Li W, et al
    U.S.-Japan cooperative medical sciences program: 22nd International Conference on Emerging Infectious Diseases in the Pacific Rim.
    Virology. 2021;555:71-77.
    PubMed     Abstract available
    
    
    
97. TAKESHITA M, Nishina N, Moriyama S, Takahashi Y, et al
    Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
    Virology. 2021;555:35-43.
    PubMed     Abstract available
    
    
    February 2021
98. NOMURA N, Matsuno K, Shingai M, Ohno M, et al
    Updating the influenza virus library at Hokkaido University -It's potential for the use of pandemic vaccine strain candidates and diagnosis.
    Virology. 2021;557:55-61.
    PubMed     Abstract available
    
    
    
99. ABDEL-MONEIM AS, Abdelwhab EM, Memish ZA
    Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines.
    Virology. 2021;558:1-12.
    PubMed     Abstract available
    
    
    
100. ISHIGAKI H, Nakayama M, Kitagawa Y, Nguyen CT, et al
     Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.
     Virology. 2021;554:97-105.
     PubMed     Abstract available
     
     
     
101. REFAEY RH, El-Ashrey MK, Nissan YM
     Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
     Virology. 2021;554:48-54.
     PubMed     Abstract available
     
     
     January 2021
102. FREIRE-PASPUEL B, Vega-Marino P, Velez A, Cruz M, et al
     Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis.
     Virology. 2021;553:154-156.
     PubMed     Abstract available
     
     
     December 2020
103. MORE SA, Patil AS, Sakle NS, Mokale SN, et al
     Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
     Virology. 2020;555:10-18.
     PubMed     Abstract available
     
     
     
104. LI L, Liang Y, Hu F, Yan H, et al
     Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients.
     Virology. 2020;551:26-35.
     PubMed     Abstract available
     
     
     
105. JIANG RD, Li B, Liu XL, Liu MQ, et al
     Bat mammalian orthoreoviruses cause severe pneumonia in mice.
     Virology. 2020;551:84-92.
     PubMed     Abstract available
     
     
     November 2020
106. YU R, Tan S, Dan Y, Lu Y, et al
     Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection.
     Virology. 2020;553:131-134.
     PubMed     Abstract available
     
     
     
107. POWELL JD, Abente EJ, Chang J, Souza CK, et al
     Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
     Virology. 2020;553:94-101.
     PubMed     Abstract available
     
     
     
108. JONES LR, Manrique JM
     Quantitative phylogenomic evidence reveals a spatially structured SARS-CoV-2 diversity.
     Virology. 2020;550:70-77.
     PubMed     Abstract available
     
     
     
109. DOBROVOLNY HM
     Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
     Virology. 2020;550:61-69.
     PubMed     Abstract available
     
     
     
110. KISHKO M, Catalan J, Swanson K, DiNapoli J, et al
     Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.
     Virology. 2020;550:21-26.
     PubMed     Abstract available
     
     
     September 2020
111. NISSLY RH, Zaman N, Ibrahim PAS, McDaniel K, et al
     Influenza C and D viral load in cattle correlates with bovine respiratory disease (BRD): Emerging role of orthomyxoviruses in the pathogenesis of BRD.
     Virology. 2020;551:10-15.
     PubMed     Abstract available
     
     
     
112. SEYED HOSSEINI E, Riahi Kashani N, Nikzad H, Azadbakht J, et al
     The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
     Virology. 2020;551:1-9.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: